This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Novo Nordisk A/s. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Innovations by Karen-Margrethe Pedersen in Insulin Formulation
Introduction
Karen-Margrethe Pedersen is a notable inventor based in Copenhagen, Denmark. She has made significant contributions to the field of diabetes treatment through her innovative work on insulin formulations. Her research and inventions have the potential to improve the quality of life for many individuals living with diabetes.
Latest Patents
Karen-Margrethe Pedersen holds a patent for a high concentration insulin formulation. This invention concerns a soluble insulin preparation comprising NϵB29-hexadecandioyl-γ-Glu-(desB30) human insulin in a concentration ranging from 1800 nmol/ml to 4200 nmol/ml. The formulation also includes Zinc ions in a concentration from 4.0 Zn/6Ins to 7.0 Zn/6Ins, Niacinamide in a concentration from 110 mM to 220 mM or treprostinil in a concentration from 0.02 μg/ml to 1 μg/ml, and Citrate in a concentration from 6 mM to 40 mM, with a pH in the range from 7.0 to 8.0. The invention further comprises a method for using the soluble insulin preparation to reduce blood glucose levels in mammals and a process for preparing these soluble insulin preparations.
Career Highlights
Karen-Margrethe Pedersen is associated with Novo Nordisk A/S, a leading global healthcare company specializing in diabetes care. Her work at Novo Nordisk has been instrumental in advancing insulin therapies and improving patient outcomes. She has a strong focus on research and development, contributing to innovative solutions in diabetes management.
Collaborations
Throughout her career, Karen-Margrethe has collaborated with esteemed colleagues such as Jeppe Sturis and Svend Havelund. These collaborations have fostered a productive environment for innovation and have led to significant advancements in insulin formulations.
Conclusion
Karen-Margrethe Pedersen's contributions to insulin formulation represent a significant advancement in diabetes treatment. Her innovative work continues to impact the lives of many individuals managing diabetes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile